Skip to main content

Oncology

lib_org_D3pZd677

About our Oncology efforts

We have a clear aspiration – to transform the lives of people with cancer by delivering meaningful advances, with the ultimate goal of curing a range of cancers. Our generational commitment to driving scientific innovation is reflected by our robust pipeline of cancer cell-directed and immuno-oncology investigational therapies, as well as the smart combination of these approaches. We are taking a diligent and broad approach, creating a collaborative research network to tap into a diversity of minds, which is vital in addressing some of the most challenging, but potentially most impactful, areas of cancer research. Simply put, for Boehringer Ingelheim, cancer care is personal, today and for generations.

Partner enquiries
Join our team

Additional resources

Selection of projects in February 2024

Phase 1 studies are usually designed with an emphasis on the assessment of safety and tolerability of an investigational drug in a small group of people for the first time. It can include healthy participants or participants with the disease.

Phase 2 studies are usually designed to begin to evaluate the efficacy of an investigational drug in a higher number of participants with the disease, and often used to obtain dose-ranging information. Safety also continues to be assessed during this phase.

BI 764532
Oncology_partnered_FastTrack
Oncology

BI 764532

DLL3/CD3 T-cell engager | ep-NEC
BI 764532
Oncology_partnered_FastTrack
Oncology

BI 764532

DLL3/CD3 T-cell engager | SCLC
BI 764532
Oncology_partnered_FastTrack
Oncology

BI 764532

DLL3/CD3 T-cell engager | LC-NEC

Phase 3 studies are designed to confirm the data of Phase 2 studies for an investigational drug. Large numbers of participants with the disease are generally involved to obtain safety and efficacy data to evaluate the overall benefit-risk relationship of an investigational drug to provide an adequate basis for regulatory approvals. Given the size of these studies and to ensure a representative sample of patients, they are often conducted across several countries.

Indication abbreviations

BTC: advanced biliary tract cancer

DDLPS: Dedifferentiated liposarcoma

ep-NEC: Extra-pulmonary neuroendocrine carcinoma

NSCLC: Non-small-cell lung cancer

SCLC:  Small-cell lung cancer

LC-NEC: large cell neuroendocrine carcinoma

Related Press Releases